Where Novonix stands after its latest Filing
Revenue for the twelve months was $6m, down 4.1% on a year earlier, a smaller fall than the 27.3% decline a quarter earlier. Free-cash-flow margin fell to -1822.5% from -656.9% a year earlier. The diluted share count is up 37.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 7 financial-health checks.
Our models give no value for Novonix at present, so past values are not shown.